New Drug Combination Extends Survival by Over 8 Months in Aggressive Small-Cell Lung Cancer
- Medical researchers at the European Society for Medical Oncology congress in Madrid on Oct.
- The study demonstrated a 58% reduction in the relative risk of death during the observation period.
- Small-cell lung cancer accounts for roughly 13% to 15% of all lung cancer diagnoses globally, according to ANSA and la Repubblica.
Medical researchers at the European Society for Medical Oncology congress in Madrid on Oct. 24, 2026, revealed that combining the bispecific antibody tarlatamab with the immunotherapeutic drug durvalumab extends median overall survival to 21.1 months in extensive-stage small-cell lung cancer patients, an increase of more than eight months compared with standard maintenance therapy. corriere.it reported that the phase 3 DeLLphi-305 trial enrolled 563 patients who had completed initial chemotherapy and immunotherapy without disease progression.
Trial Results Reveal Survival Gains In Advanced Microcytoma
The study demonstrated a 58% reduction in the relative risk of death during the observation period. Tiseo noted in reporting from corriere.it that the percentage of patients alive at one year reached approximately 80%, compared to 53% with durvalumab alone as reported by ANSA. Progression-free survival increased significantly, with the median time before disease progression rising from 1.9 months to 7.4 months, according to la Repubblica.
Aggressive Nature Of Small-Cell Lung Cancer
Small-cell lung cancer accounts for roughly 13% to 15% of all lung cancer diagnoses globally, according to ANSA and la Repubblica. More than 90% of cases occur in current or former tobacco smokers, as detailed by corriere.it. The disease spreads rapidly and frequently forms distant metastases before detection, with roughly 60% to 70% of patients diagnosed only after the malignancy has reached an extensive stage.
Mechanism Of The Tarlatamab And Durvalumab Combination
Mondosanita reported that tarlatamab functions as a biological bridge by binding to cancer cells and recruiting immune T cells directly to the tumor site. Simultaneously, durvalumab blocks the PD-L1 protein to remove inhibitory signals on the immune system. Tiseo explained to corriere.it that utilizing this dual approach during maintenance therapy targets residual cancer cells before they begin active progression.
Future Steps And Treatment Integration In Oncology
Oncologists attending the Madrid congress indicated that introducing tarlatamab earlier in the therapeutic pathway could alter how clinicians manage aggressive forms of lung cancer. La Repubblica noted that because the trial data represents an interim analysis with a relatively short follow-up period, researchers must gather long-term safety and durability data to establish definitive clinical guidelines.
